Donald E. Ingber to Receive Lifetime Achievement Award at InnoPharm-2026

Some scientific discoveries redefine an entire field. Others reshape the future of medicine itself. For decades, Donald E. Ingber, M.D., Ph.D. has done both.

In recognition of his extraordinary contributions to biomedical engineering and pharmaceutical innovation, CO-IN Symposia is proud to announce that Donald E. Ingber, Founding Director and Core Faculty of the Wyss Institute for Biologically Inspired Engineering at Harvard University, will receive the Lifetime Achievement Award at the 2nd International Conference on Innovations in Pharma R&D (InnoPharm-2026).

The award ceremony will take place during InnoPharm-2026, scheduled for November 2–4, 2026, in Boston, Massachusetts, USA, where global leaders from academia, healthcare, biotechnology, pharmaceutical companies, and regulatory organizations will convene to explore the latest advances driving the future of drug discovery and development.

Over a career spanning decades, Dr. Ingber has transformed the way scientists understand the relationship between engineering and biology. His pioneering work has challenged conventional approaches to disease modeling and therapeutic development, creating technologies that bring laboratory science closer to real human physiology.

Among his most celebrated achievements is the development of Organ-on-a-Chip technology, an innovation that has revolutionized pharmaceutical research by recreating the functions of human organs on microengineered devices. This breakthrough has accelerated drug discovery, improved safety evaluation, and opened new possibilities for precision medicine while reducing reliance on traditional preclinical models.

As the founding leader of the Wyss Institute, Dr. Ingber has built one of the world's most influential centers for biologically inspired engineering, fostering interdisciplinary collaborations that have translated scientific discoveries into technologies impacting healthcare, diagnostics, regenerative medicine, and biotechnology. His research continues to influence scientists, clinicians, entrepreneurs, and innovators across the globe.

Beyond his scientific achievements, Dr. Ingber has become a symbol of translational innovation—demonstrating how fundamental research can evolve into life-changing medical solutions. His dedication to mentoring emerging researchers and building collaborative scientific communities has inspired generations of scientists to pursue bold ideas that address global healthcare challenges.

The InnoPharm-2026 Lifetime Achievement Award celebrates not only a remarkable scientific career but also a lasting legacy of innovation that continues to shape the future of pharmaceutical research and biomedical science.

"Scientific progress is driven by individuals whose vision extends beyond today's challenges. Dr. Donald E. Ingber exemplifies that vision through decades of pioneering research, technological innovation, and leadership. It is our privilege to recognize his exceptional contributions with the InnoPharm-2026 Lifetime Achievement Award."

CO-IN Symposia warmly congratulates Dr. Donald E. Ingber on this prestigious honor and looks forward to celebrating his remarkable achievements with the global scientific community in Boston this November.

---

About InnoPharm-2026

The 2nd International Conference on Innovations in Pharma R&D (InnoPharm-2026) will be held on November 2–4, 2026, in Boston, Massachusetts, USA. The conference brings together leading researchers, pharmaceutical executives, clinicians, biotechnology innovators, regulators, and technology developers to exchange ideas and showcase the latest breakthroughs in drug discovery, AI-driven pharmaceutical research, precision medicine, biologics, and next-generation therapeutic technologies.